Invion

Invion EBIT CAGR 10Y

The EBIT CAGR (10 Year) of Invion (IVX.AX) as of Oct 13, 2026 is -4.43 %. In the previous year, EBIT CAGR (10 Year) was -4.43 % — a change of 0.00% (lower).

EBIT CAGR 10Y

-4.43 %

YoY

0.00%

Last updated:

EBIT CAGR (10 Year) of Invion is 2026 -4.43 % . EBIT CAGR (10 Year) of Invion was 2025 -4.43 % . It decreases by 0.00% lower compared to the previous year.

The Invion EBIT CAGR 10Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 10Y
Date
EBIT CAGR 10Y
Jan 1, 2019
-4.43 AUD
Jan 1, 2020
-4.43 AUD
Jan 1, 2021
-4.43 AUD
Jan 1, 2022
-4.43 AUD
Jan 1, 2023
-4.43 AUD
Jan 1, 2024
-4.43 AUD
Jan 1, 2025
-4.43 AUD
Jan 1, 2026
-4.43 AUD
The Invion EBIT CAGR 10Y history
YEAREBIT CAGR 10YYoY
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %0.00%
-4.43 %—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

EBIT CAGR (10 Year) of Invion is -4.43 % in 2026.

On Eulerpool you can find the complete historical development of EBIT CAGR (10 Year) Invion since 2006 – with annual values, charts, and detailed analysis.

The 10-year EBIT CAGR shows the long-term compound annual growth rate of operating earnings.

To evaluate EBIT CAGR (10 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (10 Year).

EBIT CAGR (10 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (10 Year)'s Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — Invion

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Invion